Effects of Buprenorphine in a Preclinical Orthotopic Tumor Model of Ovarian Carcinoma in Female CB17 SCID Mice
Natalie A. Bratcher(Animal Welfare Institute), Susan Bolin(AbbVie (United States)), Xin Huang(Capital Medical University), Andrew Oleksijew(Abbott (United States)), David J. Frost(Abbott Fund), Letty M Medina(AbbVie (United States)), Jonathan A. Hickson(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States))
Journal of the American Association for Laboratory Animal Science
August 15, 2019
Cited by 6
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation
|Journal of Medicinal Chemistry|2002|421
Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer
|Journal of Medicinal Chemistry|2004|364
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
|Clinical Cancer Research|2008|211